Skip to main content
. 2021 Dec 9;225(7):1141–1150. doi: 10.1093/infdis/jiab593

Figure 4.

Figure 4.

Neutralization of SARS-CoV-2 variants of concern by sera from healthy donors without prior infection vaccinated with mRNA1273 × 2 doses, n = 27 (A), BNT162b2 × 2 doses, n = 28 (B), or Ad26.COV2.S × 1 dose, n = 20 (C). The pNT50 (defined as the titer at which the serum achieves 50% neutralization of the relevant SARS-CoV-2 wild-type pseudovirus entry into ACE2-expressing 293T cells) is shown for each donor against the SARS-CoV-2 wild-type (Wuhan) strain, the Beta, Gamma, and Delta viral variants, and SARS-CoV-1. The GMT, fold-change relative to neutralization of wild type, proportion above the LLOD (horizontal dotted line at pNT50 = 12), and degree of statistical evidence relative to wild type are shown above each group. Nonparametric (Friedman) test P values relative to wild type are denoted as ns, ∗ P < .05, ∗∗ P < .01, ∗∗∗ P < .001. For each group the horizontal line denotes the geometric mean titer, and whiskers extend to 95% confidence intervals. Abbreviations: GMT, geometric mean titer; LLOD, lower limit of detection; ns, not significant; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.